Fate Therapeutics Inc (FATE) Return on Sales by Net Profit

Brandmark of Fate Therapeutics, Inc. (FATE)

The sales margin level on the GURU.Markets chart, where the -2619.60 indicator expresses the state of the metric, confirms the transparency of capital management and the high scientific qualification of Fate Therapeutics, Inc. (FATE) leadership. The trend depends on clinical test outcomes, while external R&D funding is balanced by partnerships. Fate Therapeutics, Inc. (FATE) is implementing accessible iPSC immunotherapy, creating scalable cellular products for mass oncology treatment.

FATE: Fate Pharma Company Net Profitability 07/04/2022 - 11/20/2026

Analytical breakdowns for Fate Therapeutics, Inc.

- share price and expert price forecast:
Summary company analytics:fatetherapeutics.com - FATE
Flagship merchandise of Fate Therapeutics Corp

The scalability of the Fate Therapeutics, Inc. (FATE) stem cell platform enables a reduction in drug production costs, which directly impacts the net profit margin. This indicator measures the portion of profit in every dollar of revenue after all expenses are deducted, allowing investors to assess the operational efficiency of capital management and determine the actual investment attractiveness of the asset.

Competitor analysis

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|Net Profit Rate DCTH (Delcath Corp)|YMAB: Net Sales Margin|AURA - Company Sales Margin|CADL (Candel Therapeutics Inc.) - Net Sales Margin|Net Return on Sales ARAY (Accuray)|Return on Sales by Net Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Net Margin|Net Margin Citius Oncology, Inc. CTOR|HURA - Return on Sales by Net Profit|protaratx.com - Net Sales Margin|WHWK (aadibio.com) - Net Return on Sales|TCRX (TScan Therapeutics, Inc.) - Return on Sales by Net Profit|Net Margin Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - Net Sales Margin|CVM (CEL-SCI Corporation) - Company Net Profitability|Net Sales Margin OSTX|Net Sales Margin Radiopharm Theranostics Ltd (RADX)|Net Sales Margin ARTV (Artiva Biotherapeutics)|Net Sales Margin Adlai Nortye Ltd. ANL|Veru Inc - Net Sales Margin|Company Sales Margin Tempest Therapeutics TPST|XLO: Net Sales Margin|Enochian BioSciences (RENB) - Net Sales Margin|Return on Sales by Net Profit MURA|Kairos Pharma Ltd - Net Profit Margin|Net Sales Margin OKUR|CytoMed Therapeutics Limited (GDTC) - Net Profitability Margin|Net Sales Margin CRIS (Curis, Inc.)|APLM: Net Return on Sales|Tharimmune Corporation - Net Sales Margin|ADVB: Net Margin|GNPX: Net Sales Margin|CLDI (Calidi Biotherapeutics Inc.) - Net Margin|Net Margin Sunshine Biopharma, Inc.|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)